Literature DB >> 31480928

Effects of ACA Expansion of Dependent Coverage on Hospital-Based Care of Young Adults With Early Psychosis.

Susan H Busch1, Ezra Golberstein1, Howard H Goldman1, Christine Loveridge1, Robert E Drake1, Ellen Meara1.   

Abstract

OBJECTIVE: Since 2010, the Affordable Care Act has required private health plans to extend dependent coverage to adults up to age 26. Because psychosis often begins in young adulthood, expanded private insurance benefits may affect early psychosis treatment. The authors examined changes in insurance coverage and hospital-based service use among young adults with psychosis before and after this change.
METHODS: The study included a national sample (2006-2013) of discharges and emergency department visits. Using a difference-in-differences study design, the authors compared changes in insurance coverage (measured as payer source), per capita admissions, and 30-day readmissions for psychosis before and after ACA dependent coverage expansion among targeted individuals (ages 20-25) and a comparison group (ages 27-29).
RESULTS: After dependent coverage expansion, hospitalization for psychosis among young adults was 5.8 percentage points more likely to be reimbursed by private insurance among the targeted age group (ages 20-25), compared with the slightly older age group (ages 27-29). Dependent coverage expansion was not associated with changes in overall insurance coverage, per capita admissions, or 30-day readmission for psychosis.
CONCLUSIONS: Although dependent coverage expansion was unrelated to changes in use of hospital-based treatments for psychosis among young adults, care was more likely to be covered by private insurance, and coverage of these hospitalizations by public insurance decreased. This shift from public to private insurance may reduce public spending on young-adult treatments for early-episode psychosis but may leave young adults without coverage for rehabilitation services.

Entities:  

Keywords:  Insurance; Psychosis; Schizophrenia

Mesh:

Year:  2019        PMID: 31480928      PMCID: PMC7605277          DOI: 10.1176/appi.ps.201800492

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  14 in total

Review 1.  Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation.

Authors:  Philip D Harvey; Robert K Heaton; William T Carpenter; Michael F Green; James M Gold; Michael Schoenbaum
Journal:  Schizophr Res       Date:  2012-04-13       Impact factor: 4.939

Review 2.  Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.

Authors:  Diana O Perkins; Hongbin Gu; Kalina Boteva; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

3.  Economic grand rounds: financing first-episode psychosis services in the United States.

Authors:  Howard H Goldman; Mustafa Karakus; William Frey; Kirsten Beronio
Journal:  Psychiatr Serv       Date:  2013-06       Impact factor: 3.084

4.  Access to health insurance and the use of inpatient medical care: evidence from the Affordable Care Act young adult mandate.

Authors:  Yaa Akosa Antwi; Asako S Moriya; Kosali I Simon
Journal:  J Health Econ       Date:  2014-11-28       Impact factor: 3.883

5.  "They Treat you a Different Way:" Public Insurance, Stigma, and the Challenge to Quality Health Care.

Authors:  Anna C Martinez-Hume; Allison M Baker; Hannah S Bell; Isabel Montemayor; Kristan Elwell; Linda M Hunt
Journal:  Cult Med Psychiatry       Date:  2017-03

6.  What It Will Take to Make Coordinated Specialty Care Available to Anyone Experiencing Early Schizophrenia: Getting Over the Hump.

Authors:  Lisa Dixon
Journal:  JAMA Psychiatry       Date:  2017-01-01       Impact factor: 21.596

7.  Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program.

Authors:  John M Kane; Delbert G Robinson; Nina R Schooler; Kim T Mueser; David L Penn; Robert A Rosenheck; Jean Addington; Mary F Brunette; Christoph U Correll; Sue E Estroff; Patricia Marcy; James Robinson; Piper S Meyer-Kalos; Jennifer D Gottlieb; Shirley M Glynn; David W Lynde; Ronny Pipes; Benji T Kurian; Alexander L Miller; Susan T Azrin; Amy B Goldstein; Joanne B Severe; Haiqun Lin; Kyaw J Sint; Majnu John; Robert K Heinssen
Journal:  Am J Psychiatry       Date:  2015-10-20       Impact factor: 18.112

8.  An ACA provision increased treatment for young adults with possible mental illnesses relative to comparison group.

Authors:  Brendan Saloner; Benjamin Lê Cook
Journal:  Health Aff (Millwood)       Date:  2014-08       Impact factor: 6.301

9.  Cost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients.

Authors:  Teresa B Gibson; Yonghua Jing; Edward Kim; Erin Bagalman; Sara Wang; Richard Whitehead; Quynh-Van Tran; Jalpa A Doshi
Journal:  Manag Care       Date:  2010-08

10.  Twelve-Month Health Care Use and Mortality in Commercially Insured Young People With Incident Psychosis in the United States.

Authors:  Michael Schoenbaum; Jason M Sutherland; Andre Chappel; Susan Azrin; Amy B Goldstein; Agnes Rupp; Robert K Heinssen
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

View more
  3 in total

1.  Association of Follow-Up After an Emergency Department Visit for Mental Illness with Utilization Based Outcomes.

Authors:  Kimberley H Geissler; Michael I Cooper; John E Zeber
Journal:  Adm Policy Ment Health       Date:  2021-01-12

2.  Insurance Status and Continuity for Young Adults With First-Episode Psychosis.

Authors:  Ezra Golberstein; Susan H Busch; Kyaw Sint; Robert A Rosenheck
Journal:  Psychiatr Serv       Date:  2021-05-11       Impact factor: 4.157

3.  Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.

Authors:  Alex Z Fu; Jacqueline A Pesa; Susan Lakey; Carmela Benson
Journal:  BMC Psychiatry       Date:  2022-04-09       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.